CSL to complete contracted manufacture of AstraZeneca vaccines in 2022

CSL has confirmed it will continue manufacturing AstraZeneca’s Covid-19 vaccine into next year, following reports it would cease production early due to local preferences for the Pfizer and Moderna vaccines.

The full contract with the federal government to produce approximately 50 million doses of Vaxzevria will be met, with any unused doses donated to countries in the region, said federal health minister Greg Hunt.

“We are pleased to say that the Australian Government and AstraZeneca trusted us as their partners to help the country respond to the emerging crisis through the most effective solution available: vaccination,” CSL chairman Brian McNamee told attendees at the company’s AGM this week.

Nine News reports that 12.43 million doses have been administered to Australians, with 18.59 million doses of Pfizer’s vaccine and 335,378 of Moderna’s.

TGA approval was given in February for the manufacture of AstraZeneca’s vaccine in Australia by CSL’s Seqirus business.

Picture: Darrian Traynor/Getty Images

Subscribe to our free @AuManufacturing newsletter here.